Please use a PC Browser to access Register-Tadawul
Get It
Artiva Biotherapeutics Showcases AlloNK As First Off-The-Shelf NK Cell Therapy Demonstrating Deep B-Cell Depletion With Favorable Tolerability Profile
Artiva Biotherapeutics, Inc. ARTV | 4.55 | -27.78% |
